VARICELLA AND HERPES ZOSTER: HISTORY AND PERSPECTIVES OF PROPHYLACTIC VACCINATION


Cite item

Full Text

Abstract

Varicella-zoster virus (VZV) afflicts most of mankind. The idea on immunity to VZV infection is not now adequately complete. VZV-induced infections are characterized by high morbidity, mortality, and incidence rates. Morbidity and other indices have increased significantly since the prophylactic vaccine containing the live attenuated Oka strain was introduced in a number of countries. The experience with prophylactic vaccination in the USA showed the highest efficiency of a two-dose varicella vaccination schedule. To prevent endogenous VZV reactivation and herpes zoster development, the vaccine has been designed on the basis of the same strain Oka, which is able to prevent the disease in some cases and, in its development, to reduce its severity. The review also gives the data of trials of an inactivated recombinant subunit DNA vaccine for preventing primary VZV infection and for searching for new vaccine administration routes.

Full Text

Restricted Access

About the authors

A. S KAZANOVA

I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences, Moscow

Email: pendelbus@gmail.com

V. F LAVROV

I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences, Moscow

D. V DUBODELOV

I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences, Moscow

S. N KUZIN

I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences, Moscow

References

  1. Zerboni L., Berarducci B., Rajamani J. Varicella-zoster virus glycoprotein E is a critical determinant of virulence in the SCID mouse-human model of neuropathogenesis. J Virol. 2011; 85 (1): 98-111.
  2. Jones L., Black A..P, Malavige G.N. Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur. J. Immunol. 2007; 37 (12): 3393-3403.
  3. Nagel M.A., Choe A., Traktinskiy I. Varicella-zoster virus transcriptome in latently infected human ganglia. J. Virol. 2011; 85 (5): 2276-2287.
  4. Richard A., Santos J., Padilla A. Antigenic variation of varicella zoster virus Fc receptor gE: loss of a major B cell epitope in the ectodomain. Virology 1998; 249 (1): 21-31.
  5. Haumont M., Jurdan M., Kangro H. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization. J. Med. Virol. 1997; 53 (1): 63-68.
  6. Wirgart B.Z., Estrada V., Jackson W. A novel varicella-zoster virus gE mutation discovered in two Swedish isolates. J. Clin. Virol. 2006; 37 (2): 134-136.
  7. Natoli S., Ciotti M., Paba P. A novel mutation of varicella-zoster virus associated to fatal hepatitis. J. Clin. Virol. 2006; 37 (1): 72-74.
  8. Michalik D.E., Steinberg S.P., Larussa P.S. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J. Infect. Dis. 2008; 197 (7): 944-949.
  9. Johnson J.A., Bloch K.C., Dang B.N. Varicella reinfection in a seropositive physician following occupational exposure to localized zoster. Clin. Infect. Dis. 2011; 52 (7): 907-909.
  10. Takahashi M., Asano Y., Kamiya H. Development of varicella vaccine. J. Infect. Dis. 2008; 197 (suppl 2): S41-S44.
  11. Grinfeld E., Ross A., Forster T. Genome-wide reduction in transcriptomal profiles of varicella-zoster virus vaccine strains compared with parental Oka strain using long oligonucleotide microarrays. Virus Genes 2009; 38 (1): 19-29.
  12. Yamanishi K. Molecular analysis of the Oka vaccine strain of varicella-zoster virus. J. Infect. Dis. 2008; 197 (suppl 2): S45-S48.
  13. Kuter B.J., Weibel R.E., Guess H.A. Oka/Merck Varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9: 643- 647.
  14. Seward J.F., Marin M., Vazquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J. Infect. Dis. 2008; 197 (suppl. 2): S82-S89.
  15. Krause P.R., Klinman D.M. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J. Pediatr. 1995; 127: 518-525.
  16. White C.J., Kuter B.J., Hildebrand C.S. et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991; 87: 604- 610.
  17. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm. Rep. 1996; 45: 1-36.
  18. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 1999; 48: 1-5.
  19. Rasch G., Hellenbrand W. Germany adds varicella vaccine to the national vaccination programme. Euro Surveill 2004; 8: 1.
  20. Roush S.W., Murphy T.V. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. J.A.M.A. 2007; 298: 2155-2163.
  21. Sharrar R.G., LaRussa P., Galea S.A. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19 (78): 916-923.
  22. LaRussa P., Steinberg S.P., Shapiro E. Varicella vaccine revisited. Nat. Med. 2000; 6 (12): 1299-1300.
  23. Civen R., Chaves S.S., Jumaan A. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr. Infect. Dis. J. 2009; 28 (11): 954-959.
  24. Marin M., Güris D., Chaves S.S. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2007; 56 (RR-4): 1-40.
  25. Galil K., Fair E., Mountcastle N. Younger age at vaccination may increase risk of varicella vaccine failure. J. Infect. Dis. 2002; 186: 102-105.
  26. Haddad M.B., Hill M.B., Pavia A.T. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics 2005; 115: 1488-1493.
  27. Terada K., Niizuma T., Yagi Y. Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination. J. Med. Virol. 2000; 62 (1): 46-51.
  28. White C.J., Kuter B.J., Hildebrand C.S. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics. 199; 87 (5): 604 - 610.
  29. Tsolia M., Gershon A.A., Steinberg S.P. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J. Pediatr. 1990; 116 (2): 184-190.
  30. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 19994; 48: 1-5.
  31. Galea S.A., Sweet A., Beninger P. The safety profile of varicella vaccine: a 10-year review. J. Infect. Dis. 2008; 197 (suppl. 2): S165-S169.
  32. Gershon A.A., Chen J., Davis L. Distribution of latent varicella zoster virus in sensory ganglia and gut after vaccination and wild-type infection: evidence for viremic spread. In: 34th International Herpesvirus Workshop 2009 Ithaca. New York; 2009.
  33. Krause P.R., Klinman D.M. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat. Med. 2000; 6 (4): 451-454.
  34. Hardy I., Gershon A.A., Steinberg S.P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N. Engl. J. Med. 1991; 325 (22): 1545-1550.
  35. Brunell P.A., Argaw T. Chickenpox attributable to a vaccine virus contracted from a vaccinee with zoster. Pediatrics 2000; 106 (2): E28.
  36. Brisson M., Edmunds W.J. Varicella vaccination in England and Wales: cost-utility analysis. Arch. Dis. Child. 2003; 88 (10): 862-869.
  37. Mehta S.K., Cohrs R.J., Forghani B. et al. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J. Med. Virol. 2004; 72 (1): 174-179.
  38. Patel M.S., Gebremariam A., Davis M.M. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infec. Control Hosp. Epidemiol. 2008; 29: 1157-1163.
  39. Jardine A., Conaty S.J., Vally H. Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization? Epidemiol. Infect. 2011; 139 (5): 658-665.
  40. Oxman M.N., Levin M.J. Vaccination against herpes zoster and postherpetic neuralgia. Shingles Prevention Study Group. J. Infect. Dis. 2008; 197 (suppl. 2): S228-S236.
  41. Macaladad N., Marcano T., Guzman M. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007; 25 (11): 2139-2144.
  42. Davies J., Hallworth J.A., McLeish P. Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus. Med. Microbiol. Immunol. 1994; 183 (2): 105-117.
  43. Hayward A.R., Buda K., Levin M.J. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunol. 1994; 7 (1): 31-36.
  44. Gershon A.A. Varicella-zoster virus infections. Pediatr. Rev. 2008; 29 (1): 5-10.
  45. Levin M.J., Ellison M.C., Zerbe G.O. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18: 2915-2920.
  46. Redman R.L., Nader S., Zerboni L. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J. Infect. Dis. 1997; 176: 578-585.
  47. Hata A., Asanuma H., Rinki M. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med. 2002; 347 (1): 26-34.
  48. Jacquet A., Haumont M., Massaer M. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Vaccine 2002; 20 (11-12): 1593-1602.
  49. Hasan U.A., Harper D.R., Wren B.W. Immunization with a DNA vaccine expressing a truncated form of varicella zoster virus glycoprotein E. Vaccine 2002; 20 (9-10):1308-1315.
  50. Terada K., Niizuma T., Ogita S. Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine. Vaccine 2002; 20 (31-32): 3638-3643.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies